Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Risk Reduction in Coronary Heart Disease (SPREK!)

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Sorlandet Hospital HF
Oslo University Hospital
Information provided by (Responsible Party):
Sissel Ledang, Sorlandet Hospital HF Identifier:
First received: July 5, 2007
Last updated: April 11, 2014
Last verified: April 2014
Study hypothesis: Multifactorial risk reduction in coronary heart disease can reduce the risk of new coronary heart disease and death

Condition Intervention
Coronary Heart Disease
Behavioral: smoking cessation
Drug: betablocker, diuretics, ACEI, ARB,
Drug: statins, ezetimibe
Behavioral: training
Biological: influenza vaccine
Drug: metformin, glimepiride, insulin
Behavioral: weight reduction

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Risk Reduction in Coronary Heart Disease - a Prospective Randomized Study

Resource links provided by NLM:

Further study details as provided by Sorlandet Hospital HF:

Primary Outcome Measures:
  • New cardiovascular events (MACE) [ Time Frame: 3 years ]

Estimated Enrollment: 2000
Study Start Date: September 2007
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Multifactorial intervention
Smoking cessation betablocker, diuretics, ACEI, ARB, statins, ezetimibe training influenza vaccine weight reduction metformin, glimepiride, insulin
Behavioral: smoking cessation
NRT and varenicline
Drug: betablocker, diuretics, ACEI, ARB,
blood pressure control according to ESC guidelines
Drug: statins, ezetimibe
Cholesterol reduction according to ESC guidelines
Behavioral: training
daily walking
Biological: influenza vaccine
vaccine (FLuarix, Influvac etc)
Drug: metformin, glimepiride, insulin
s.glucose control according to ESC guidelines
Behavioral: weight reduction
diet tips
No Intervention: Controll
no intervention


Ages Eligible for Study:   18 Years to 79 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • acute myocardial infarction, CABG or PCI

Exclusion Criteria:

  • Age < 18 and age > 80
  • pregnant
  • critical illness
  • drug abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00679237

Contact: Jarle Jortveit, MD 004737014000

Sorlandet Hospital Recruiting
Arendal, Norway
Contact: Jarle Jortveit, MD    00473714000   
Sponsors and Collaborators
Sorlandet Hospital HF
Oslo University Hospital
Study Chair: Serena Tonstad, Ullevaal University Hospital
  More Information

Responsible Party: Sissel Ledang, Sorlandet Hospital HF Identifier: NCT00679237     History of Changes
Other Study ID Numbers: S-07041a (REK)
Study First Received: July 5, 2007
Last Updated: April 11, 2014

Additional relevant MeSH terms:
Heart Diseases
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Cardiovascular Diseases
Vascular Diseases
Arterial Occlusive Diseases
Adrenergic beta-Antagonists
Immunologic Factors
Physiological Effects of Drugs
Hypoglycemic Agents
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Natriuretic Agents
Anti-Arrhythmia Agents
Immunosuppressive Agents processed this record on April 25, 2017